fluzoparib + camrelizumab + capecitabine

This combination regimen consists of fluzoparib (a PARP1/2 inhibitor), camrelizumab (an anti-PD-1 monoclonal antibody), and capecitabine (an oral chemotherapy prodrug). Developed primarily by Jiangsu Hengrui Pharmaceuticals, these agents are being investigated together in various clinical settings. Specifically, a Phase II trial sponsored by Chongqing University Cancer Hospital is evaluating the sequential use of fluzoparib, either alone or in combination with camrelizumab and capecitabine, following chemoradiotherapy for untreated pan-solid tumors. These include surgically resectable rectal cancer and locally advanced unresectable non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and cervical cancer. Fluzoparib works by inhibiting DNA repair in HR-deficient cells, camrelizumab enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway, and capecitabine acts as a cytotoxic agent by interfering with DNA synthesis.

Brand names

AiRuiYiAiRuiKaXeloda

Other names

fuzuloparibfluzoparib, fluzoparib + camrelizumab, fluzoparib + capecitabine